{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:18:17Z","timestamp":1785161897869,"version":"3.55.0"},"reference-count":157,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by four-repeat tau deposition in various cell types and anatomical regions, and can manifest as several clinical phenotypes, including the most common phenotype, Richardson\u2019s syndrome. The limited availability of biomarkers for PSP relates to the overlap of clinical features with other neurodegenerative disorders, but identification of a growing number of biomarkers from imaging is underway. One way to increase the reliability of imaging biomarkers is to combine different modalities for multimodal imaging. This review aimed to provide an overview of the current state of PSP hybrid imaging by combinations of positron emission tomography (PET) and magnetic resonance imaging (MRI). Specifically, combined PET and MRI studies in PSP highlight the potential of [18F]AV-1451 to detect tau, but also the challenge in differentiating PSP from other neurodegenerative diseases. Studies over the last years showed a reduced synaptic density in [11C]UCB-J PET, linked [11C]PK11195 and [18F]AV-1451 markers to disease progression, and suggested the potential role of [18F]RO948 PET for identifying tau pathology in subcortical regions. The integration of quantitative global and regional gray matter analysis by MRI may further guide the assessment of reduced cortical thickness or volume alterations, and diffusion MRI could provide insight into microstructural changes and structural connectivity in PSP. Challenges in radiopharmaceutical biomarkers and hybrid imaging require further research targeting markers for comprehensive PSP diagnosis.<\/jats:p>","DOI":"10.3390\/cells12242776","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T06:01:07Z","timestamp":1701842467000},"page":"2776","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Joachim","family":"Strobel","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Ulm University, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-7806","authenticated-orcid":false,"given":"Ambros J.","family":"Beer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-2223","authenticated-orcid":false,"given":"Nico","family":"Sollmann","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, University Hospital Ulm, 89081 Ulm, Germany"},{"name":"Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany"},{"name":"TUM-Neuroimaging Center, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-9270","authenticated-orcid":false,"given":"Jan","family":"Kassubek","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Ulm University, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_2","first-page":"1563","article-title":"Four-Repeat Tauopathies: Current Management and Future Treatments","volume":"17","author":"VandeVrede","year":"2020","journal-title":"Neurother. J. Am. Soc. Exp. NeuroTher."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Respondek","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","article-title":"Cellular and pathological heterogeneity of primary tauopathies","volume":"16","author":"Chung","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/WCO.0000000000000707","article-title":"Corticobasal degeneration: Advances in clinicopathology and biomarkers","volume":"32","author":"Svenningsson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-12-802395-2.00025-0","article-title":"Tauopathies","volume":"Volume 145","author":"Kovacs","year":"2017","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_9","first-page":"919","article-title":"Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy","volume":"25","author":"Greene","year":"2019","journal-title":"Continuum"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117293","DOI":"10.1016\/j.jns.2020.117293","article-title":"Disease course and treatment patterns in progressive supranuclear palsy: A real-world study","volume":"421","author":"Morgan","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M., Heine, J., Doll-Lee, J., P\u00f6tter-Nerger, M., and Zeitzschel, M. (2023). The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J. Neurol., Online ahead of print.","DOI":"10.1007\/s00415-023-12006-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1007\/s00415-023-11714-1","article-title":"Progressive supranuclear palsy\u2019s economical burden: The use and costs of healthcare resources in a large health provider in Israel","volume":"270","author":"Barer","year":"2023","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Barer, Y., Chodick, G., Cohen, R., Grabarnik-John, M., Ye, X., Zamudio, J., and Gurevich, T. (2022). Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel. Brain Sci., 12.","DOI":"10.3390\/brainsci12091126"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cortex.2020.12.019","article-title":"Spatial attention and spatial short term memory in PSP and Parkinson\u2019s disease","volume":"137","author":"Smith","year":"2021","journal-title":"Cortex A J. Devoted Study Nerv. Syst. Behav."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mds.27038","article-title":"Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s00415-020-10360-1","article-title":"Diffusion tensor imaging analysis in three progressive supranuclear palsy variants","volume":"268","author":"Whitwell","year":"2021","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"572976","DOI":"10.3389\/fneur.2020.572976","article-title":"Neuroimaging Advances in Parkinson\u2019s Disease and Atypical Parkinsonian Syndromes","volume":"11","author":"Saeed","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_18","first-page":"1754","article-title":"18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy","volume":"63","author":"Messerschmidt","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ciarmiello, A., and Mansi, L. (2016). PET-CT and PET-MRI in Neurology, Springer International Publishing.","DOI":"10.1007\/978-3-319-31614-7"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Panic, N., Leoncini, E., de Belvis, G., Ricciardi, W., and Boccia, S. (2013). Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083138"},{"key":"ref_21","first-page":"755","article-title":"An introduction to PET and SPECT neuroreceptor quantification models","volume":"42","author":"Ichise","year":"2001","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_22","first-page":"100155","article-title":"Imaging pathological tau in atypical parkinsonisms: A review","volume":"7","author":"Mena","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cri\u0219an, G., Moldovean-Cioroianu, N.S., Timaru, D.-G., Andrie\u0219, G., C\u0103inap, C., and Chi\u0219, V. (2022). Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095023"},{"key":"ref_24","first-page":"1541","article-title":"18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism","volume":"56","author":"Hellwig","year":"2015","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_25","first-page":"1741","article-title":"Differential Diagnosis of Parkinsonism Based on Deep Metabolic Imaging Indices","volume":"63","author":"Wu","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/01616412.2017.1312211","article-title":"The utility of FDG-PET in the differential diagnosis of Parkinsonism","volume":"39","author":"Brajkovic","year":"2017","journal-title":"Neurol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.45.11.1995","article-title":"Early differential diagnosis of Parkinson\u2019s disease with 18F-fluorodeoxyglucose and positron emission tomography","volume":"45","author":"Eidelberg","year":"1995","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mds.21933","article-title":"Abnormal metabolic networks in atypical parkinsonism","volume":"23","author":"Eckert","year":"2008","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1007\/s00415-023-11824-w","article-title":"Brain FDG-PET correlates of saccadic disorders in early PSP","volume":"270","author":"Pin","year":"2023","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Seiffert, A.P., G\u00f3mez-Grande, A., Alonso-G\u00f3mez, L., M\u00e9ndez-Guerrero, A., Villarejo-Galende, A., G\u00f3mez, E.J., and S\u00e1nchez-Gonz\u00e1lez, P. (2022). Differences in Striatal Metabolism in 18FFDG PET in Parkinson\u2019s Disease and Atypical Parkinsonism. Diagnostics, 13.","DOI":"10.3390\/diagnostics13010006"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-023-01025-x","article-title":"Diagnostic accuracy of cerebral 18FFDG PET in atypical parkinsonism","volume":"13","author":"Houssein","year":"2023","journal-title":"EJNMMI Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.29581","article-title":"Automatic covariance pattern analysis outperforms visual reading of 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in variant progressive supranuclear palsy","volume":"38","author":"Buchert","year":"2023","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Small","year":"2002","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41531-017-0023-3","article-title":"Imaging tau pathology in Parkinsonisms","volume":"3","author":"Coakeley","year":"2017","journal-title":"NPJ Park. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00259-012-2102-3","article-title":"Longitudinal imaging of Alzheimer pathology using 11CPIB, 18FFDDNP and 18FFDG PET","volume":"39","author":"Ossenkoppele","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-130032","article-title":"PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy","volume":"36","author":"Kepe","year":"2013","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ricci, M., Cimini, A., Camedda, R., Chiaravalloti, A., and Schillaci, O. (2021). Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313002"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-160698","article-title":"Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-\u03b2 and Tau in Parkinson\u2019s Disease1","volume":"55","author":"Buongiorno","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jie, C.V.M.L., Treyer, V., Schibli, R., and Mu, L. (2021). Tauvid\u2122: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer\u2019s Disease. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020110"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mohammadi, Z., Alizadeh, H., Marton, J., and Cumming, P. (2023). The Sensitivity of Tau Tracers for the Discrimination of Alzheimer\u2019s Disease Patients and Healthy Controls by PET. Biomolecules, 13.","DOI":"10.3390\/biom13020290"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of F-18-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Normandin","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00415-019-09566-9","article-title":"18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy","volume":"267","author":"Nicastro","year":"2020","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"18 FAV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ana.25893","article-title":"Sensitivity-Specificity of Tau and Amyloid \u03b2 Positron Emission Tomography in Frontotemporal Lobar Degeneration","volume":"88","author":"Ghirelli","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","article-title":"Cross-interaction of tau PET tracers with monoamine oxidase B: Evidence from in silico modelling and in vivo imaging","volume":"46","author":"Murugan","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: A novel in vivo tau imaging ligand for Alzheimer\u2019s disease","volume":"134","author":"Okamura","year":"2011","journal-title":"Brain A J. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.jalz.2014.04.013","article-title":"In vivo tau imaging: Obstacles and progress","volume":"10","author":"Villemagne","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/alzrt240","article-title":"Assessing THK523 selectivity for tau deposits in Alzheimer\u2019s disease and non-Alzheimer\u2019s disease tauopathies","volume":"6","author":"Furumoto","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13139-017-0484-7","article-title":"Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies","volume":"52","author":"Choi","year":"2017","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnagi.2018.00174","article-title":"Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology","volume":"10","author":"Brendel","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer\u2019s disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer\u2019s disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"ref_53","first-page":"671","article-title":"Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease","volume":"59","author":"Harada","year":"2018","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: Current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"ref_55","first-page":"996","article-title":"In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317","volume":"58","author":"Betthauser","year":"2017","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","article-title":"Neuroimaging-pathological correlations of 18FTHK5351 PET in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_57","first-page":"35","article-title":"Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer\u2019s disease: A combined positron emission tomography\/magnetic resonance imaging study","volume":"9","author":"Sone","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/mds.27643","article-title":"In vivo binding of a tau imaging probe, 11 CPBB3, in patients with progressive supranuclear palsy","volume":"34","author":"Endo","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/RLU.0000000000002949","article-title":"Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study","volume":"45","author":"Blazhenets","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Uzuegbunam, B.C., Librizzi, D., and Hooshyar Yousefi, B. (2020). PET Radiopharmaceuticals for Alzheimer\u2019s Disease and Parkinson\u2019s Disease Diagnosis, the Current and Future Landscape. Molecules, 25.","DOI":"10.3390\/molecules25040977"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Weng, C.-C., Hsiao, I.-T., Yang, Q.-F., Yao, C.-H., Tai, C.-Y., Wu, M.-F., Yen, T.-C., Jang, M.-K., and Lin, K.-J. (2020). Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy. Molecules, 25.","DOI":"10.3390\/molecules25071750"},{"key":"ref_63","first-page":"P1104","article-title":"[P3\u2013378]: First-in-human pet study with 18 F-AM-PBB3 and 18 F-PM-PBB3","volume":"13","author":"Shimada","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Clinical Utility of 18 F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy","volume":"36","author":"Li","year":"2021","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_65","first-page":"3471","article-title":"A case of tauopathy with auditory agnosia and dysprosody diagnosed by 18FPM-PBB3 tau PET scan","volume":"42","author":"Mashima","year":"2021","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/mds.28867","article-title":"In Vivo 18 F-APN-1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross-Sectional and Longitudinal Findings","volume":"37","author":"Zhou","year":"2022","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"117440","DOI":"10.1016\/j.jns.2021.117440","article-title":"A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by 18FPM-PBB3 tau PET","volume":"425","author":"Ishizuchi","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00259-022-05964-w","article-title":"Additive value of 18FPI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome","volume":"50","author":"Katzdobler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of 18FPI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rullmann, M., Brendel, M., Schroeter, M.L., Saur, D., Levin, J., Perneczky, R.G., Tiepolt, S., Patt, M., Mueller, A., and Villemagne, V.L. (2022). Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer\u2019s Disease. Biomolecules, 12.","DOI":"10.3390\/biom12030458"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.1021\/acs.jmedchem.1c00861","article-title":"PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer\u2019s Disease and Other Tauopathies","volume":"64","author":"Kroth","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","article-title":"18F-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy","volume":"9","author":"Brendel","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"103402","DOI":"10.1016\/j.nicl.2023.103402","article-title":"Symptomatology in 4-repeat tauopathies is associated with data-driven topology of 18F-PI-2620 tau-PET signal","volume":"38","author":"Palleis","year":"2023","journal-title":"NeuroImage Clin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo2,3-cpyridin-1-yl)isoquinolin-5-amine ((18)F-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)","volume":"59","author":"Walji","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_77","first-page":"93","article-title":"In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls","volume":"60","author":"Betthauser","year":"2019","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/brain\/awab248","article-title":"Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages","volume":"144","author":"Pascoal","year":"2021","journal-title":"Brain A J. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with 18FMK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_80","first-page":"108","article-title":"Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects","volume":"63","author":"Gogola","year":"2022","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jlcr.3894","article-title":"High-yield synthesis of a tau PET radioligand and its nonradioactive ligand using an alternative protection and deprotection strategy","volume":"64","author":"Kim","year":"2021","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00259-022-06065-4","article-title":"18FRO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes","volume":"50","author":"Santillo","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","article-title":"A multicenter comparison of 18Fflortaucipir, 18FRO948, and 18FMK6240 tau PET tracers to detect a common target ROI for differential diagnosis","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","article-title":"Radiosynthesis, In Vitro and In Vivo Evaluation of 18FCBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies","volume":"12","author":"Lindberg","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neulet.2018.08.010","article-title":"Positron emission tomography imaging of the \u03b3-aminobutyric acid system","volume":"691","author":"Andersson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jnen\/60.5.403","article-title":"Cortical synapse loss in progressive supranuclear palsy","volume":"60","author":"Bigio","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/mds.28188","article-title":"Synaptic Loss in Primary Tauopathies Revealed by 11 CUCB-J Positron Emission Tomography","volume":"35","author":"Holland","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.29421","article-title":"Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo 11 CUCB-J Positron Emission Tomography Study","volume":"38","author":"Holland","year":"2023","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/brain\/awab282","article-title":"Molecular pathology and synaptic loss in primary tauopathies: An 18F-AV-1451 and 11C-UCB-J PET study","volume":"145","author":"Holland","year":"2022","journal-title":"Brain A J. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00259-021-05425-w","article-title":"Have (R)-11CPK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies","volume":"49","author":"Chauveau","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"739130","DOI":"10.3389\/fimmu.2021.739130","article-title":"PET Imaging of Neuroinflammation in Alzheimer\u2019s Disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00259-021-05379-z","article-title":"TSPO imaging in animal models of brain diseases","volume":"49","author":"Lavisse","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.apsb.2020.08.006","article-title":"Recent developments on PET radiotracers for TSPO and their applications in neuroimaging","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-022-05952-0","article-title":"Interplay of tau and functional network connectivity in progressive supranuclear palsy: A 18FPI-2620 PET\/MRI study","volume":"50","author":"Aghakhanyan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00429-017-1507-y","article-title":"18FAV-1451 binding to neuromelanin in the substantia nigra in PD and PSP","volume":"223","author":"Coakeley","year":"2018","journal-title":"Brain Struct. Funct."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/brain\/awx347","article-title":"Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"141","author":"Cope","year":"2018","journal-title":"Brain A J. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2021.01.016","article-title":"In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies","volume":"101","author":"Mak","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/ana.25911","article-title":"Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy","volume":"88","author":"Malpetti","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"120514","DOI":"10.1016\/j.jns.2022.120514","article-title":"Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy","volume":"444","author":"Matsuoka","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"105226","DOI":"10.1016\/j.parkreldis.2022.11.018","article-title":"Performance of 18FRO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy","volume":"106","author":"Pawlik","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","article-title":"11CPK11195 binding in Alzheimer disease and progressive supranuclear palsy","volume":"90","author":"Passamonti","year":"2018","journal-title":"Neurology"},{"key":"ref_104","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain A J. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2020.09.039","article-title":"The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study","volume":"81","author":"Seckin","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.parkreldis.2019.07.001","article-title":"Multimodal neuroimaging relationships in progressive supranuclear palsy","volume":"66","author":"Sintini","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"119763","DOI":"10.1016\/j.neuroimage.2022.119763","article-title":"An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607)","volume":"264","author":"Tagai","year":"2022","journal-title":"NeuroImage"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2017.12.016","article-title":"Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer\u2019s disease in progressive supranuclear palsy","volume":"48","author":"Whitwell","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102152","DOI":"10.1016\/j.nicl.2019.102152","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2020","journal-title":"NeuroImage Clin."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.27546","article-title":"MRI Outperforms 18FAV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy","volume":"34","author":"Whitwell","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_111","first-page":"318","article-title":"Clinical, MRI and 18F-FDG-PET\/CT analysis of progressive supranuclear palsy","volume":"80","author":"Zhao","year":"2020","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12031-007-0029-0","article-title":"Diffusion tensor imaging (DTI)-based white matter mapping in brain research: A review","volume":"34","author":"Assaf","year":"2008","journal-title":"J. Mol. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0006-3495(94)80775-1","article-title":"MR diffusion tensor spectroscopy and imaging","volume":"66","author":"Basser","year":"1994","journal-title":"Biophys. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00702-017-1700-4","article-title":"Differentiation of atypical Parkinson syndromes","volume":"124","author":"Kassubek","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/WCO.0000000000000578","article-title":"MRI-based neuroimaging: Atypical parkinsonisms and other movement disorders","volume":"31","author":"Kassubek","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/mrm.22924","article-title":"Diffusion tensor imaging and beyond","volume":"65","author":"Tournier","year":"2011","journal-title":"Magn. Reson. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.bbadis.2014.08.002","article-title":"Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review","volume":"1842","author":"Abhinav","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.sult.2021.07.006","article-title":"Diffusion-Weighted Imaging: Recent Advances and Applications","volume":"42","author":"Grussu","year":"2021","journal-title":"Semin. Ultrasound CT MR"},{"key":"ref_119","first-page":"254","article-title":"The physical and biological basis of quantitative parameters derived from diffusion MRI","volume":"2","author":"Winston","year":"2012","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.neuroimage.2011.08.043","article-title":"How and how not to correct for CSF-contamination in diffusion MRI","volume":"59","author":"Bells","year":"2012","journal-title":"NeuroImage"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/awv361","article-title":"Free-water imaging in Parkinson\u2019s disease and atypical parkinsonism","volume":"139","author":"Planetta","year":"2016","journal-title":"Brain A J. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.irn.2018.10.003","article-title":"Hybrid PET-MRI Applications in Movement Disorders","volume":"144","author":"Tondo","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.semnuclmed.2021.04.003","article-title":"Pitfalls on PET\/MRI","volume":"51","author":"Afaq","year":"2021","journal-title":"Semin. Nucl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.semnuclmed.2015.01.001","article-title":"Motion correction options in PET\/MRI","volume":"45","author":"Catana","year":"2015","journal-title":"Semin. Nucl. Med."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Catana, C. (2020). Attenuation correction for human PET\/MRI studies. Phys. Med. Biol., 65.","DOI":"10.1088\/1361-6560\/abb0f8"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1002\/hbm.24314","article-title":"From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies","volume":"39","author":"Chen","year":"2018","journal-title":"Hum. Brain Mapp."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.irn.2018.07.026","article-title":"Hybrid PET\/MRI Methodology","volume":"141","author":"Aiello","year":"2018","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2967\/jnumed.120.261032","article-title":"Evaluation of Deep Learning-Based Approaches to Segment Bowel Air Pockets and Generate Pelvic Attenuation Maps from CAIPIRINHA-Accelerated Dixon MR Images","volume":"63","author":"Sari","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fnins.2019.00782","article-title":"MRI-Driven PET Image Optimization for Neurological Applications","volume":"13","author":"Zhu","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13139-016-0393-1","article-title":"PET\/MRI: Technical Challenges and Recent Advances","volume":"50","author":"Jung","year":"2016","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00330-019-06442-y","article-title":"Highly accelerated time-of-flight magnetic resonance angiography using spiral imaging improves conspicuity of intracranial arterial branches while reducing scan time","volume":"30","author":"Greve","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jon.12791","article-title":"Novel Ultrafast Spiral Head MR Angiography Compared to Standard MR and CT Angiography","volume":"31","author":"Greve","year":"2021","journal-title":"J. Neuroimaging"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00062-019-00789-x","article-title":"Magnetic Resonance Imaging of the Brain Using Compressed Sensing\u2014Quality Assessment in Daily Clinical Routine","volume":"30","author":"Monch","year":"2020","journal-title":"Clin. Neuroradiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e210313","DOI":"10.1148\/ryai.210313","article-title":"Exploring the Acceleration Limits of Deep Learning Variational Network-based Two-dimensional Brain MRI","volume":"4","author":"Radmanesh","year":"2022","journal-title":"Radiol. Artif. Intell."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/mrm.25347","article-title":"Wave-CAIPI for highly accelerated 3D imaging","volume":"73","author":"Bilgic","year":"2015","journal-title":"Magn. Reson. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-022-28896-3","article-title":"Tau deposition patterns are associated with functional connectivity in primary tauopathies","volume":"13","author":"Franzmeier","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1148\/radiol.2453061703","article-title":"MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy","volume":"246","author":"Quattrone","year":"2008","journal-title":"Radiology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.016","article-title":"A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson\u2019s disease","volume":"54","author":"Quattrone","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/mds.28007","article-title":"Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study","volume":"35","author":"Nigro","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.28992","article-title":"Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson\u2019s Disease","volume":"37","author":"Quattrone","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: Advances in diagnosis and management","volume":"73","author":"Coughlin","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14737175.2018.1489241","article-title":"The diagnosis of progressive supranuclear palsy: Current opinions and challenges","volume":"18","author":"Ali","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"694872","DOI":"10.3389\/fneur.2021.694872","article-title":"Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care","volume":"12","author":"Bluett","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2967\/jnmt.120.261862","article-title":"PET\/MRI, Part 2: Technologic Principles","volume":"49","author":"Currie","year":"2021","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1088\/0031-9155\/57\/21\/R119","article-title":"A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology","volume":"57","author":"Erlandsson","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11307-017-1146-y","article-title":"Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology","volume":"20","author":"Alavi","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"ref_147","first-page":"44","article-title":"Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates","volume":"11","author":"Marquis","year":"2023","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Gallivanone, F., Stefano, A., Canevari, C., Messa, C., Gilardi, M.C., and Castiglioni, I. (November, January 24). PVE correction in PET from PVE affected images. Proceedings of the 2009 IEEE Nuclear Science Symposium Conference Record (NSS\/MIC), Orlando, FL, USA.","DOI":"10.1109\/NSSMIC.2009.5401688"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cpet.2015.09.002","article-title":"MR Imaging-Guided Partial Volume Correction of PET Data in PET\/MR Imaging","volume":"11","author":"Erlandsson","year":"2016","journal-title":"PET Clin."},{"key":"ref_150","first-page":"1875","article-title":"MRI-based attenuation correction for PET\/MRI: A novel approach combining pattern recognition and atlas registration","volume":"49","author":"Hofmann","year":"2008","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"118248","DOI":"10.1016\/j.neuroimage.2021.118248","article-title":"Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer\u2019s disease","volume":"238","author":"Lu","year":"2021","journal-title":"NeuroImage"},{"key":"ref_152","first-page":"904","article-title":"Correction for partial volume effects in PET: Principle and validation","volume":"39","author":"Rousset","year":"1998","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/mds.27619","article-title":"Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy","volume":"34","author":"Ali","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.4103\/2141-9248.121221","article-title":"Progressive supranuclear palsy misdiagnosed as Parkinson\u2019s disease: A case report and review of literature","volume":"3","author":"Owolabi","year":"2013","journal-title":"Ann. Med. Health Sci. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/cts.12884","article-title":"Precision Medicine, AI, and the Future of Personalized Health Care","volume":"14","author":"Johnson","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40478-016-0391-7","article-title":"An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability","volume":"4","author":"Kurz","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/brain\/awaa276","article-title":"18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"143","author":"Iaccarino","year":"2020","journal-title":"Brain A J. Neurol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/24\/2776\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:00Z","timestamp":1760132040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/24\/2776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":157,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cells12242776"],"URL":"https:\/\/doi.org\/10.3390\/cells12242776","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}